{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T09:27:26Z","timestamp":1793698046070,"version":"4.5.1"},"reference-count":39,"publisher":"The Journal of Rheumatology","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"accepted":{"date-parts":[[2026,4,8]]},"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Autologous hematopoietic cell transplantation (HCT) is an effective treatment for a subset of patients with systemic sclerosis (SSc). Unfortunately, relapse is a significant problem, with no available tests to predict relapse. We studied whether relapse is associated with pre- or post-HCT serum levels of SSc-related autoantibodies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The cohort comprised 38 consecutive evaluable patients with SSc who underwent HCT at a single center and were followed for a median of 33 months. Sixteen patients (42%) relapsed at a median of 14 months post-HCT. Autoantibody levels were determined by immunoassays.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Regarding pre-HCT autoantibodies, in univariate analyses, the cumulative incidence of relapse (CIR) was lower in anti-RNA polymerase III (ARA)-positive than ARA-negative patients (hazard ratio [HR] 0.21,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.04). Conversely, the CIR was higher among patients with positive anti-Ro52, although this difference was not statistically significant (HR 2.90,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.053). The CIR was similar in patients positive and negative for antitopoisomerase antibody (ATA; ie, Scl-70) or antinuclear antibody (ANA). In bivariate analyses that included older age as a risk factor for relapse, pre-HCT ARA was still associated with relapse (HR 0.21,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.04). This was not the case for Ro52 (HR 2.21,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.16). Regarding post-HCT autoantibody level trajectory, there was no significant difference between patients with vs without relapse.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Positive ARA pre-HCT is associated with reduced relapse risk, and post-HCT autoantibodies do not appear to be associated with relapse risk.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3899\/jrheum.2025-0987","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T12:20:25Z","timestamp":1776255625000},"page":"992-1001","source":"Crossref","is-referenced-by-count":1,"title":["Autoantibodies and Relapse of Systemic Sclerosis After Autologous Hematopoietic Cell Transplantation"],"prefix":"10.3899","volume":"53","author":[{"given":"Daniel","family":"Levin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"May","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Kawasoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caylib","family":"Durand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Osman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyein","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iman","family":"Hemmati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Woo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorothy","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Howlett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faisal M.","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Storek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2026,4,15]]},"reference":[{"key":"2026110300451622000_53.9.992.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60982-3"},{"key":"2026110300451622000_53.9.992.2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.6368"},{"key":"2026110300451622000_53.9.992.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1703327"},{"key":"2026110300451622000_53.9.992.4","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.3390\/cells11233912","article-title":"Hematopoietic cell transplantation for systemic sclerosis\u2014a review","volume":"11","author":"Levin","year":"2022","journal-title":"Cells"},{"key":"2026110300451622000_53.9.992.5","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3324\/haematol.2019.230128","article-title":"Autologous stem cell transplantation for progressive systemic sclerosis: a prospective non-interventional study from the European Society for Blood and Marrow Transplantation Autoimmune Disease Working Party","volume":"106","author":"Henes","year":"2021","journal-title":"Haematologica"},{"key":"2026110300451622000_53.9.992.6","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217058"},{"key":"2026110300451622000_53.9.992.7","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1080\/14397595.2017.1416920","article-title":"Autologous haematopoietic stem cell transplantation for Japanese patients with systemic sclerosis: long-term follow-up on a phase II trial and treatment-related fatal cardiomyopathy","volume":"28","author":"Nakamura","year":"2018","journal-title":"Mod Rheumatol"},{"key":"2026110300451622000_53.9.992.8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-02-072389"},{"key":"2026110300451622000_53.9.992.9","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/j.bbmt.2016.06.007","article-title":"Comorbidities, alcohol use disorder, and age predict outcomes after autologous hematopoietic cell transplantation for lymphoma","volume":"22","author":"Graf","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"2026110300451622000_53.9.992.10","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2017.56"},{"key":"2026110300451622000_53.9.992.11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)62114-X"},{"key":"2026110300451622000_53.9.992.12","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s00432-024-05815-1","article-title":"High-dose chemotherapy and autologous hematopoietic stem cell transplantation for progressive systemic sclerosis: a retrospective study of outcome and prognostic factors","volume":"150","author":"Pyka","year":"2024","journal-title":"J Cancer Res Clin Oncol"},{"key":"2026110300451622000_53.9.992.13","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac549"},{"key":"2026110300451622000_53.9.992.14","first-page":"451","article-title":"Analysis of anti\u2013topoisomerase I antibodies in patients with systemic sclerosis before and after autologous stem cell transplantation","volume":"56","author":"Henes","year":"2017","journal-title":"Rheumatology"},{"key":"2026110300451622000_53.9.992.15","first-page":"28","article-title":"Molecular recognition patterns of anti-topoisomerase I-antibodies in patients with systemic sclerosis before and after autologous stem cell transplantation","volume":"36","author":"Glaeser","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"2026110300451622000_53.9.992.16","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1002\/art.43072","article-title":"Autologous nonmyeloablative hematopoietic stem cell transplantation for diffuse cutaneous systemic sclerosis: identifying disease risk factors for toxicity and long-term outcomes in a prospective, single-arm trial","volume":"77","author":"Georges","year":"2025","journal-title":"Arthritis Rheumatol"},{"key":"2026110300451622000_53.9.992.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.10.048"},{"key":"2026110300451622000_53.9.992.18","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1093\/jalm\/jfab140","article-title":"The International Consensus on ANA Patterns (ICAP) in 2021-the 6th workshop and current perspectives","volume":"7","author":"Chan","year":"2022","journal-title":"J Appl Lab Med"},{"key":"2026110300451622000_53.9.992.19","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-017-1338-5"},{"key":"2026110300451622000_53.9.992.20","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41409-020-0978-2","article-title":"Cardiac safe hematopoietic stem cell transplantation for systemic sclerosis with poor cardiac function: a pilot safety study that decreases neutropenic interval to 5 days","volume":"56","author":"Burt","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"2026110300451622000_53.9.992.21","doi-asserted-by":"crossref","first-page":"6023","DOI":"10.1093\/rheumatology\/keaf392","article-title":"Anti-RNA polymerase III antibodies in systemic sclerosis: prevalence and clinical associations from a systematic review and meta-analysis","volume":"64","author":"Elhannani","year":"2025","journal-title":"Rheumatology"},{"key":"2026110300451622000_53.9.992.22","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/art.38219","article-title":"Prevalence of anti-RNA polymerase III antibodies in systemic sclerosis: new data from a French cohort and a systematic review and meta-analysis","volume":"66","author":"Sobanski","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2026110300451622000_53.9.992.23","doi-asserted-by":"publisher","DOI":"10.1136\/ard.59.12.975"},{"key":"2026110300451622000_53.9.992.24","doi-asserted-by":"publisher","DOI":"10.1006\/jaut.2002.0595"},{"key":"2026110300451622000_53.9.992.25","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1007\/s10067-019-04806-9","article-title":"Analysis of anti-RNA polymerase III antibodies in Chinese Han systemic sclerosis patients","volume":"39","author":"Liu","year":"2020","journal-title":"Clin Rheumatol"},{"key":"2026110300451622000_53.9.992.26","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep290"},{"key":"2026110300451622000_53.9.992.27","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s12016-018-8718-8","article-title":"Antinuclear antibodies in systemic sclerosis: an update","volume":"58","author":"Stochmal","year":"2020","journal-title":"Clin Rev Allergy Immunol"},{"key":"2026110300451622000_53.9.992.28","first-page":"41","article-title":"Clinical features of systemic sclerosis patients with anti-RNA polymerase III antibody in a single centre in Spain","volume":"37","author":"Callejas-Moraga","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"2026110300451622000_53.9.992.29","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.160867"},{"key":"2026110300451622000_53.9.992.30","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.2024-1063"},{"key":"2026110300451622000_53.9.992.31","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2021-221926"},{"key":"2026110300451622000_53.9.992.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2005.03.005"},{"key":"2026110300451622000_53.9.992.33","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1186\/s13075-015-0871-3","article-title":"Serological epitope profile of anti-Ro52-positive patients with systemic autoimmune rheumatic diseases","volume":"17","author":"Infantino","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"2026110300451622000_53.9.992.34","doi-asserted-by":"crossref","first-page":"103536","DOI":"10.1016\/j.autrev.2024.103536","article-title":"Prevalence of anti-Ro52-kDa\/SSA (TRIM21) antibodies and associated clinical phenotype in systemic sclerosis: data from a French cohort, a systematic review and meta-analysis","volume":"23","author":"Martel","year":"2024","journal-title":"Autoimmun Rev"},{"key":"2026110300451622000_53.9.992.35","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s13075-023-03141-4","article-title":"Anti-Ro52 positivity is associated with progressive interstitial lung disease in systemic sclerosis-an exploratory study","volume":"25","author":"Hamberg","year":"2023","journal-title":"Arthritis Res Ther"},{"key":"2026110300451622000_53.9.992.36","doi-asserted-by":"publisher","DOI":"10.1186\/ar3763"},{"key":"2026110300451622000_53.9.992.37","doi-asserted-by":"publisher","DOI":"10.1186\/ar628"},{"key":"2026110300451622000_53.9.992.38","doi-asserted-by":"crossref","first-page":"5538","DOI":"10.1093\/rheumatology\/keab257","article-title":"Autologous haematopoietic stem cell transplantation restores the suppressive capacity of regulatory B cells in systemic sclerosis patients","volume":"60","author":"Lima-J\u00fanior","year":"2021","journal-title":"Rheumatology"},{"key":"2026110300451622000_53.9.992.39","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1038\/s41409-025-02684-1","article-title":"Definition of relapse criteria in patients with rapidly progressive systemic sclerosis treated with autologous haemopoietic stem cell transplantation","volume":"60","author":"Del Papa","year":"2025","journal-title":"Bone Marrow Transplant"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.2025-0987","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T08:45:27Z","timestamp":1793695527000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.2025-0987"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,15]]},"references-count":39,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9,1]]},"published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.3899\/jrheum.2025-0987"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.2025-0987","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,15]]}}}